OCUL OCULAR THERAPEUTIX, INC
Pharmaceutical Preparations · Nasdaq · SEC CIK 1393434 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY-9.7%
TTM net income YoY-30.9%
TTM EPS YoY-0.7%
Revenue 3-yr CAGR-4.4%
Net income 3-yr CAGR—
Margins
Gross margin87.3%
Operating margin-680.9%
Net margin-648.6%
FCF margin-530.0%
EBITDA margin-667.4%
Returns
ROE-93.5%
ROA-64.3%
ROIC (approx.)—
Asset turnover0.10x
Leverage & solvency
Liabilities / assets27.2%
Debt / equity0.00x
Current ratio9.12x
Interest coverage-30.59x
Cash quality & payout
Operating cash flow / net income0.77x
Accruals ratio-14.5%
Payout ratio—
Capex / revenue27.6%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY20242024-12-31 |
|---|---|---|
| Income statement | ||
| Revenue | $51.95M | $63.72M |
| Cost of revenue | $6.57M | $5.63M |
| Gross profit | $45.38M | $58.10M |
| R&D expense | $197.10M | $127.64M |
| SG&A expense | $64.38M | $60.65M |
| Operating income | -$270.02M | -$171.78M |
| Interest expense | $11.84M | $13.58M |
| Income tax | $0 | $0 |
| Net income | -$265.94M | -$193.51M |
| EBITDA | -$265.69M | -$168.00M |
| EPS (basic) | -1.42 | -1.22 |
| EPS (diluted) | -1.42 | -1.22 |
| Weighted avg. shares (diluted) | 187.24M | 158.27M |
| Balance sheet | ||
| Cash & equivalents | $737.06M | $393.72M |
| Receivables | $30.65M | $32.39M |
| Inventory | $3.56M | $3.04M |
| Current assets | $782.13M | $440.99M |
| PP&E, net | $19.68M | $9.39M |
| Total assets | $808.06M | $457.94M |
| Current liabilities | $50.81M | $41.35M |
| Total liabilities | $153.75M | $142.59M |
| Shareholders' equity | $654.31M | $315.34M |
| Shares outstanding | 215.93M | 157.75M |
| Cash flow statement | ||
| Operating cash flow | -$204.88M | -$134.68M |
| Capital expenditure | $12.01M | $1.29M |
| Free cash flow | -$216.89M | -$135.97M |
| Investing cash flow | -$11.88M | -$1.29M |
| Financing cash flow | $561.72M | $332.11M |
| Depreciation & amortization | $4.32M | $3.79M |
| Stock-based compensation | $43.18M | $33.11M |
Free plan shows the latest 2 periods; Pro shows all 14 🔒
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.